Under this collaboration, SD Pharma will enhance Oncopeptides’ commercial reach in regions and hospitals beyond its’ core focus areas, the company describes further. The partnership leverages the coordinated efforts of Medical Science Liaisons (MSLs), responsible for clinical education and medical support, and Regional Access Managers (RAMs), who manage treatment access and pharmacy logistics.

“SD Pharma’s established track record and extensive healthcare professional relationships position them as an excellent partner to further extend the reach of Pepaxti in Spain,” says Sofia Heigis, CEO of Oncopeptides. “This collaboration perfectly complements our existing national efforts and significantly advances our goal to serve an unmet medical need.”

Activities by SD Pharma are expected to commence in Q3 2025.